Time Trends and Prognostic Factors for Overall Survival in Myxoid Liposarcomas: A Population-Based Study.

Q2 Medicine

Sarcoma Pub Date : 2020-09-22 eCollection Date: 2020-01-01 DOI:10.1155/2020/2437850

Jules Lansu, Winan J Van Houdt, Michael Schaapveld, Iris Walraven, Michiel A J Van de Sande, Vincent K Y Ho, Rick L Haas

{"title":"Time Trends and Prognostic Factors for Overall Survival in Myxoid Liposarcomas: A Population-Based Study.","authors":"Jules Lansu, Winan J Van Houdt, Michael Schaapveld, Iris Walraven, Michiel A J Van de Sande, Vincent K Y Ho, Rick L Haas","doi":"10.1155/2020/2437850","DOIUrl":null,"url":null,"abstract":"Background: The purpose of this study was to evaluate the overall survival (OS) and associated characteristics for patients with Myxoid Liposarcoma (MLS) over time in The Netherlands.Methods: A population-based study was performed of patients with primary localized (n = 851) and metastatic (n = 50) MLS diagnosed in The Netherlands between 1989 and 2016, based on data from the National Cancer Registry.Results: The median age of the MLS patients was 49 years, and approximately two-thirds was located in the lower limb. An association was revealed between age and the risk of having a Round Cell (RC) tumor. OS rates for primary localized MLS were 93%, 83%, 78%, and 66% after 1, 3, 5, and 10 years, respectively. The median OS for patients with metastatic disease at diagnosis was 10 months. Increasing age (Hazard Ratio (HR) 1.05, p=0.00), a tumor size >5 cm (HR 2.18; p=0.00), and tumor location (trunk HR 1.29; p=0.09, upper limb HR 0.83; p=0.55, and \"other\" locations HR 2.73; p=0.00, as compared to lower limb) were independent prognostic factors for OS. The percentage of patients treated with radiotherapy (RT) increased over time, and preoperative RT gradually replaced postoperative RT. In contrast to patients with localized disease, significant improvement of OS was observed in patients with metastatic disease over time.Conclusions: In this large nationwide cohort, tumor size and tumor location were independent prognostic factors for OS. Furthermore, a higher probability of an RC tumor with increasing age was suggested. An increased use of RT over the years did not translate into improved OS for localized MLS.","PeriodicalId":21431,"journal":{"name":"Sarcoma","volume":"2020 ","pages":"2437850"},"PeriodicalIF":0.0000,"publicationDate":"2020-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7528038/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sarcoma","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2020/2437850","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The purpose of this study was to evaluate the overall survival (OS) and associated characteristics for patients with Myxoid Liposarcoma (MLS) over time in The Netherlands.

Methods: A population-based study was performed of patients with primary localized (n = 851) and metastatic (n = 50) MLS diagnosed in The Netherlands between 1989 and 2016, based on data from the National Cancer Registry.

Results: The median age of the MLS patients was 49 years, and approximately two-thirds was located in the lower limb. An association was revealed between age and the risk of having a Round Cell (RC) tumor. OS rates for primary localized MLS were 93%, 83%, 78%, and 66% after 1, 3, 5, and 10 years, respectively. The median OS for patients with metastatic disease at diagnosis was 10 months. Increasing age (Hazard Ratio (HR) 1.05, p=0.00), a tumor size >5 cm (HR 2.18; p=0.00), and tumor location (trunk HR 1.29; p=0.09, upper limb HR 0.83; p=0.55, and "other" locations HR 2.73; p=0.00, as compared to lower limb) were independent prognostic factors for OS. The percentage of patients treated with radiotherapy (RT) increased over time, and preoperative RT gradually replaced postoperative RT. In contrast to patients with localized disease, significant improvement of OS was observed in patients with metastatic disease over time.

Conclusions: In this large nationwide cohort, tumor size and tumor location were independent prognostic factors for OS. Furthermore, a higher probability of an RC tumor with increasing age was suggested. An increased use of RT over the years did not translate into improved OS for localized MLS.

Abstract Image

查看原文本刊更多论文

肌样脂肪肉瘤总生存期的时间趋势和预后因素：基于人群的研究

背景：本研究旨在评估荷兰肌样脂肪肉瘤（MLS）患者的总生存期（OS）和相关特征：本研究旨在评估荷兰肌样脂肪肉瘤（MLS）患者的总生存期（OS）和相关特征：根据荷兰国家癌症登记处的数据，对1989年至2016年间在荷兰确诊的原发性局部（n = 851）和转移性（n = 50）MLS患者进行了一项基于人群的研究：MLS患者的中位年龄为49岁，约三分之二的患者位于下肢。年龄与圆形细胞（RC）肿瘤风险之间存在关联。原发性局部 MLS 患者在 1、3、5 和 10 年后的 OS 率分别为 93%、83%、78% 和 66%。确诊时患有转移性疾病的患者的中位 OS 为 10 个月。与下肢相比，年龄增加（危险比（HR）1.05，P=0.00）、肿瘤大小大于5厘米（HR 2.18；P=0.00）和肿瘤位置（躯干HR 1.29；P=0.09，上肢HR 0.83；P=0.55，"其他 "位置HR 2.73；P=0.00）是OS的独立预后因素。随着时间的推移，接受放射治疗（RT）的患者比例增加，术前RT逐渐取代术后RT。与局部疾病患者相比，随着时间的推移，转移性疾病患者的预后明显改善：结论：在这一大型全国性队列中，肿瘤大小和肿瘤位置是影响OS的独立预后因素。结论：在这一大型全国性队列中，肿瘤大小和肿瘤位置是OS的独立预后因素，此外，随着年龄的增长，出现RC肿瘤的概率更高。多年来RT使用率的提高并没有改善局部MLS的OS。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Sarcoma Medicine-Radiology, Nuclear Medicine and Imaging

CiteScore

5.00

自引率

0.00%

发文量

审稿时长

14 weeks

期刊介绍： Sarcoma is dedicated to publishing papers covering all aspects of connective tissue oncology research. It brings together work from scientists and clinicians carrying out a broad range of research in this field, including the basic sciences, molecular biology and pathology and the clinical sciences of epidemiology, surgery, radiotherapy and chemotherapy. High-quality papers concerning the entire range of bone and soft tissue sarcomas in both adults and children, including Kaposi"s sarcoma, are published as well as preclinical and animal studies. This journal provides a central forum for the description of advances in diagnosis, assessment and treatment of this rarely seen, but often mismanaged, group of patients.